Altmetric

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium

File Description SizeFormat 
bjc201786a.pdfPublished version398.01 kBAdobe PDFView/Open
Title: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium
Authors: Goranova, T
Ennis, D
Piskorz, AM
Macintyre, G
Lewsley, LA
Stobo, J
Wilson, C
Kay, D
Glasspool, RM
Lockley, M
Brockbank, E
Montes, A
Walther, A
Sundar, S
Edmondson, R
Hall, GD
Clamp, A
Gourley, C
Hall, M
Fotopoulou, C
Gabra, H
Freeman, S
Moore, L
Jimenez-Linan, M
Paul, J
Brenton, JD
McNeish, A
Item Type: Journal Article
Abstract: Background: Investigating tumour evolution and acquired chemotherapy resistance requires analysis of sequential tumour material. We describe the feasibility of obtaining research biopsies in women with relapsed ovarian high-grade serous carcinoma (HGSC). Methods: Women with relapsed ovarian HGSC underwent either image-guided biopsy or intra-operative biopsy during secondary debulking, and samples were fixed in methanol-based fixative. Tagged-amplicon sequencing was performed on biopsy DNA. Results: We screened 519 patients in order to enrol 220. Two hundred and two patients underwent successful biopsy, 118 of which were image-guided. There were 22 study-related adverse events (AE) in the image-guided biopsies, all grades 1 and 2; pain was the commonest AE. There were pre-specified significant AE in 3/118 biopsies (2.5%). 87% biopsies were fit-for-purpose for genomic analyses. Median DNA yield was 2.87 μg, and was higher in biopsies utilising 14 G or 16 G needles compared to 18 G. TP53 mutations were identified in 94.4% patients. Conclusions: Obtaining tumour biopsies for research in relapsed HGSC is safe and feasible. Adverse events are rare. The large majority of biopsies yield sufficient DNA for genomic analyses—we recommend use of larger gauge needles and methanol fixation for such biopsies, as DNA yields are higher but with no increase in AEs.
Issue Date: 30-Mar-2017
Date of Acceptance: 3-Mar-2017
URI: http://hdl.handle.net/10044/1/48929
DOI: https://dx.doi.org/10.1038/bjc.2017.86
ISSN: 1532-1827
Publisher: Cancer Research UK
Start Page: 1294
End Page: 1301
Journal / Book Title: British Journal of Cancer
Volume: 116
Issue: 10
Copyright Statement: © The Author(s) named above 2017. This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
ovarian cancer
high grade serous carcinoma
biopsy
image-guided
methanol fixation
next-generation sequencing
tagged-amplicon sequencing
PHASE-III TRIAL
EPITHELIAL OVARIAN
CANCER GENOMICS
BREAST-CANCER
OPEN-LABEL
CHEMOTHERAPY
BEVACIZUMAB
RESISTANCE
MUTATIONS
WOMEN
Oncology & Carcinogenesis
1112 Oncology And Carcinogenesis
Publication Status: Published
Appears in Collections:Division of Surgery
Division of Cancer
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx